研究单位：[1]Shanghai Henlius Biotech[2]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China[3]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[4]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China[5]Chongqing University Cancer Hospital,Chongqing,Chongqing,China[6]Fujian Cancer Hospital,Fuzhou,Fujian,China[7]Fujian Medical University Union Hospital,Fuzhou,Fujian,China[8]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China[9]Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou,Guangdong,China[10]First Affiliated Hospital of Guangzhou University of TMC,Guangzhou,Guangdong,China[11]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,Guangzhou,Guangdong,China[12]The First Affiliated Hospital of Guangdong College of Pharmacy,Guangzhou,Guangdong,China[13]Sun Yat-sen University, Cancer Center,Guanzhou,Guangdong,China[14]The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China[15]Affiliated Hospital of Guangdong Medical University,Zhanjiang,Guangdong,China[16]Liuzhou General Hospital,Liuzhou,Guangxi,China[17]Guangxi Medical University Affiliated Tumor Hospital,Nanning,Guangxi,China[18]Affiliated Hospital of Hebei University,Baoding,Hebei,China[19]Hebei Cangzhou Central Hospital,Cangzhou,Hebei,China[20]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[21]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China[22]Henan Cancer Hospital,Zhengzhou,Henan,China[23]Hubei Cancer Hospital,Wuhan,Hubei,China[24]Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology,Wuhan,Hubei,China[25]Union Hospital, Tongji Medical College of Huazhong University of Science & Technology,Wuhan,Hubei,China[26]The 2nd Xiangya Hospital of Central South University,Changsha,Hunan,China[27]The Third Xiangya Hospital of Central South University,Changsha,Hunan,China[28]Neimenggu Chifeng Hospital,Chifeng,Inner Mongolia,China[29]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China[30]Jiangsu Province Hospital,Nanjing,Jiangsu,China[31]Nanjing Bayi Hospital,Nanjing,Jiangsu,China[32]The Affiliated Drum Tower Hospital of Nanjing University,Nanjing,Jiangsu,China[33]Nantong Tumor Hospital,Nantong,Jiangsu,China[34]Wuxi 4th People's Hospital,Wuxi,Jiangsu,China[35]Xuzhou Central Hospital,Xuzhou,Jiangsu,China[36]Northern Jiangsu People's Hospital,Yangzhou,Jiangsu,China[37]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[38]The First Hospital of Jilin University,Chang chun,Jilin,China[39]Jilin Cancer Hospital,Changchun,Jilin,China[40]Jilin Province People's Hospital,Changchun,Jilin,China[41]The Second Hospital of Dalian Medical University,Dalian,Liaoning,China[42]General Hospital of the Northern Theater of the Chinese People's Liberation Army,Shenyang,Liaoning,China[43]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China[44]The First Hospital of China Medical University,Shenyang,Liaoning,China[45]Affiliated Hospital of Qinghai University,Xining,Qinghai,China[46]Affiliated Hospital of Jining Medical University,Jining,Shandong,China[47]Jinan Central Hospital,Jinan,Shangdong,China[48]Yantai Yuhuangding Hospital,Yantai,Shangdong,China[49]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China[50]Ruijin Hospital of Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China[51]Shannxi Provincial Tumor Hospital,Xi'an,Shangxi,China[52]The 2nd Hospital of Xi'An Jiaotong University,Xi'an,Shanxi,China[53]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China[54]West China Hospital, Sichuan University,Chengdu,Sichuan,China[55]Nanchong Central Hospital,Nanchong,Sichuan,China[56]Tianjin Medical University Cancer Institute & Hospital,Tianjing,Tianjing,China[57]Yunnan Cancer Hospital,Kunming,Yunnan,China[58]Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine,Hangzhou,Zhejiang,China[59]The First Affiliat
研究目的：
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.
